Guardant Health Inc (GH)’s price-to-cash and price-to-free cash flow ratios

The price of Guardant Health Inc (NASDAQ: GH) closed at $22.61 in the last session, up 0.98% from day before closing price of $22.39. In other words, the price has increased by $+0.22 from its previous closing price. On the day, 890817 shares were traded. GH stock price reached its highest trading level at $22.89 during the session, while it also had its lowest trading level at $22.22.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Ratios:

We take a closer look at GH’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.60 and its Current Ratio is at 5.94. In the meantime, Its Debt-to-Equity ratio is 5.95 whereas as Long-Term Debt/Eq ratio is at 5.83.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Dec 04 when Joyce Meghan V. sold 100 shares for $26.34 per share. The transaction valued at 2,634 led to the insider holds 4,422 shares of the business.

Kalia Kumud sold 5,800 shares of GH for $152,954 on Dec 01. The Chief Information Officer now owns 5,926 shares after completing the transaction at $26.37 per share. On Sep 12, another insider, Kalia Kumud, who serves as the Chief Information Officer of the company, sold 2,125 shares for $32.59 each. As a result, the insider received 69,254 and left with 7,813 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GH now has a Market Capitalization of 2.74B and an Enterprise Value of 2.95B. For the stock, the TTM Price-to-Sale (P/S) ratio is 5.12 while its Price-to-Book (P/B) ratio in mrq is 11.67. Its current Enterprise Value per Revenue stands at 5.78 whereas that against EBITDA is -6.36.

Stock Price History:

Over the past 52 weeks, GH has reached a high of $41.06, while it has fallen to a 52-week low of $20.67. The 50-Day Moving Average of the stock is 25.16, while the 200-Day Moving Average is calculated to be 29.63.

Shares Statistics:

According to the various share statistics, GH traded on average about 0.57 shares per day over the past 3-months and 1.51M shares per day over the past 10 days. A total of 121.38M shares are outstanding, with a floating share count of 115.04M. Insiders hold about 5.23% of the company’s shares, while institutions hold 127.34% stake in the company. Shares short for GH as of Jan 31, 2024 were 5.54M with a Short Ratio of 3.59, compared to 5.23M on Dec 29, 2023. Therefore, it implies a Short% of Shares Outstanding of 4.57% and a Short% of Float of 4.76%.

Earnings Estimates

The company has 18 analysts who recommend its stock at the moment. On average, analysts expect EPS of -$0.87 for the current quarter, with a high estimate of -$0.52 and a low estimate of -$1.01, while EPS last year was -$1.36. The consensus estimate for the next quarter is -$0.87, with high estimates of -$0.64 and low estimates of -$1.

Analysts are recommending an EPS of between -$3.02 and -$4 for the fiscal current year, implying an average EPS of -$3.59. EPS for the following year is -$3.35, with 20 analysts recommending between -$2.42 and -$3.86.

Revenue Estimates

According to 20 analysts, the current quarter’s revenue is expected to be $149.57M. It ranges from a high estimate of $154M to a low estimate of $143.9M. As of the current estimate, Guardant Health Inc’s year-ago sales were $126.89M, an estimated increase of 17.90% from the year-ago figure. For the next quarter, 18 analysts are estimating revenue of $152.24M, an increase of 18.30% over than the figure of $17.90% in the same quarter last year. There is a high estimate of $162.6M for the next quarter, whereas the lowest estimate is $146M.

A total of 22 analysts have provided revenue estimates for GH’s current fiscal year. The highest revenue estimate was $563.07M, while the lowest revenue estimate was $552.8M, resulting in an average revenue estimate of $557.87M. In the same quarter a year ago, actual revenue was $449.54M, up 24.10% from the average estimate. Based on 22 analysts’ estimates, the company’s revenue will be $669.36M in the next fiscal year. The high estimate is $693M and the low estimate is $646.4M. The average revenue growth estimate for next year is up 20.00% from the average revenue estimate for this year.

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular